MAPT and Alzheimer disease: According to clinical case reports, the brains of patients with AD demonstrate a considerable increase in the levels of tau phosphorylated at Thr205, Ser396, and Ser404, as well as increased GSK-3β expression but decreased PP2A expression [13,64].